about
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous miceDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusThe PI3K pathway as drug target in human cancerA new view of carcinogenesis and an alternative approach to cancer therapyThe Role of Gastrin and CCK Receptors in Pancreatic Cancer and other MalignanciesRedox Control of Multidrug Resistance and Its Possible Modulation by AntioxidantsMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyStrategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and marketMet kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survivalSmall-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growthRas superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical researchModulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70A short-term in vivo model for giant cell tumor of bone.A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptorEstablishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.Morphologic characterization of osteosarcoma growth on the chick chorioallantoic membrane.Targeted therapies in epithelial ovarian cancer.Cancer stem cells and their mechanism of chemo-radiation resistanceInitiation factor eIF2-independent mode of c-Src mRNA translation occurs via an internal ribosome entry site.Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biologyMolecular mechanisms of resistance to tumour anti-angiogenic strategiesSynthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapyOverexpression of GRB2 is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma CellsRexin-G, a targeted genetic medicine for cancer.Tailoring mTOR-based therapy: molecular evidence and clinical challenges.Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditionsTargeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancersA novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma.Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma.
P2860
Q24597354-46BB1199-C5DA-4B33-B945-3681DF966DC3Q24600932-4EA36133-B59C-4760-B2F7-5D7912C6853EQ24632283-E93E804F-FA1D-4A0F-A517-E75299241EBBQ24650249-F01C346A-70A2-4512-8B94-CCA9EEBA8019Q26765244-41C548BF-FA71-415F-8375-18561502218DQ26765805-14C242F1-AAA1-40A7-AB77-B1FBEB9F5224Q26798420-94CAC94D-720E-4DFC-AED0-67859F7376EDQ27015050-7F79B531-D6D9-4F40-8C85-E8AE3FABEC74Q27316936-213B11A3-A392-44A9-BE41-40FC79918BFEQ27661276-12DF6151-D453-4195-A856-7FFCBE2EEFF3Q27690752-BDC6AA8E-5CE7-47EE-8E5C-C8D8D01300B5Q28072766-5AA19FAC-7B20-4AF0-B1E3-C4B271CFCEDAQ28472533-416E4F11-4048-4A67-B3E1-EEC4A605CDD5Q30501674-22A8C50B-31B0-44BD-B748-443EFD39925AQ30992402-8C741CB1-DC07-4180-AD73-427C1DED5E8FQ33354953-7F5A75FC-4F27-4DFA-B3FC-7CEE226BFBFFQ33536827-3CDECB19-0EE3-4C46-8EF1-30AA75F670F8Q33606699-4C045DA6-AE5F-4682-8019-AB3408BD607DQ33614696-4A92C09B-A60D-4826-B05E-93D24DE655C6Q33648488-D43C7AFE-0A55-4985-8FA9-3438A944B4EBQ33656600-EE0638E2-1A4F-49C5-9BFD-D1363D91CA5EQ33718025-26A63E53-3C93-441F-8754-F8AAED75974BQ33737986-0CECDE1D-EB9A-47A3-90EA-8444EA048690Q33898634-B4CABC9A-02A1-4639-A0B9-8AFF637F8107Q34017103-7B96E5B9-AC96-4657-B9D4-631772BAEDD8Q34041344-C87B8DA6-255F-4283-ACF7-B76CB10D014CQ34109646-AA9B3ADB-BAEF-4649-A492-64C8A7DB7364Q34294170-2CF02B71-6425-4F7F-B4E6-1C0527203C4CQ34308855-0C877E86-BB5B-4AE5-B62A-B0C401E2C780Q34565052-42CE2402-C95C-4DEF-AED1-18535E7B7300Q34632966-73CD456F-3605-400D-9C15-F7980B4F9783Q34768640-FD6E28B9-DB48-4021-B52B-C31A14ED3ED0Q34878868-DD4DEB25-5E82-4899-96FE-964DF2E80746Q34970844-DE9B7C88-03B8-471A-8E80-F67884961A92Q34973743-9BC647A6-7855-4B67-8ED1-5242007D5D49Q35027892-96AFB5F8-B139-4290-B9C4-75AC7279C2AFQ35085657-2A83C3EE-9D16-47E7-8A7B-1E821BF318F0Q35192991-74F6EB14-1BE9-4645-9DE5-323A32B4147CQ35205410-0EFB6E51-8C42-4D8E-B064-5645A1E33CA7Q35338422-02240C45-4285-45B9-B12F-60C1DF3F555D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel agents on the horizon for cancer therapy.
@en
Novel agents on the horizon for cancer therapy.
@nl
type
label
Novel agents on the horizon for cancer therapy.
@en
Novel agents on the horizon for cancer therapy.
@nl
prefLabel
Novel agents on the horizon for cancer therapy.
@en
Novel agents on the horizon for cancer therapy.
@nl
P356
P1433
P1476
Novel agents on the horizon for cancer therapy.
@en
P2093
Alex A Adjei
P304
P356
10.3322/CAAC.20003
P407
P577
2009-03-01T00:00:00Z